Patents Examined by Paul V. Ward
  • Patent number: 10730889
    Abstract: Provided are amido spirocyclic amide and sulfonamide compounds, pharmaceutical compositions comprising such compounds, and methods of treatment using such compounds.
    Type: Grant
    Filed: March 26, 2018
    Date of Patent: August 4, 2020
    Assignees: FORMA TM, LLC, Genentech, Inc.
    Inventors: Kenneth W. Bair, Timm R. Baumeister, Peter Dragovich, Xiongcai Liu, Snahel Patel, Po-Wai Yuen, Mark Zak, Guiling Zhao, Yamin Zhang, Xiaozhang Zheng
  • Patent number: 10723707
    Abstract: This invention relates to heterocyclic substituted 2-amino-quinazoline derivatives, processes for their preparation, pharmaceutical compositions, and their use in treating viral infections.
    Type: Grant
    Filed: April 8, 2019
    Date of Patent: July 28, 2020
    Assignee: Janssen Sciences Ireland Unlimited Company
    Inventors: Stefaan Julien Last, David Craig McGowan, Werner Embrechts, Serge Maria Aloysius Pieters, Tim Hugo Maria Jonckers, Pierre Jean-Marie Bernard Raboisson
  • Patent number: 10717711
    Abstract: Disclosed are compounds having the formula: wherein R1, R2, R3, and Z are as defined herein, and methods of making and using the same.
    Type: Grant
    Filed: February 27, 2019
    Date of Patent: July 21, 2020
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Adam K. Charnley, Xiaoyang Dong
  • Patent number: 10717740
    Abstract: The present application relates to crystalline propylene glycol solvate of acalabrutinib and process for preparation thereof. The propylene glycol solvate of acalabrutinib may be selected from a group of racemic propylene glycol solvate, R-propylene glycol solvate and S-propylene glycol solvate of acalabrutinib. Specifically, the present application relates to crystalline forms RSV1, RSV2, RSV3 and RSV4 of acalabrutinib. Crystalline forms RSV2 and RSV3 are stable in all conditions and has excellent physico-chemical properties. The present application also relates to crystalline form RSVS of acalabrutinib.
    Type: Grant
    Filed: June 8, 2018
    Date of Patent: July 21, 2020
    Inventors: Raja Sekhar Voguri, Vishweshwar Peddy
  • Patent number: 10702501
    Abstract: The present invention includes a composition, method of making and method of using a novel C5-substituted carbapenem antibiotic of formula 1: R1 is H or CH3 R2 is not H, and is CH3, or C1-C6 straight chain, or branched alkyl, or C3-C6 cycloalkyl group, or unsaturated alkenyl, including C?CH2; R3 is H, CH3, or a C1-C6 alkyl or cycloalkyl group, a heteroatom-substituted alkyl; and R4 is a C1 to C6 alkyl, or substituted alkyl group, especially including substituents which possess positive charge, or a hydroxyl group; or R4 is an SRa, where Ra is an unsubstituted C1 to C6 alkyl group, a substituted C1 to C6 alkyl group, or a functional group that is positively charged, or which bears a positive charge when in aqueous solution at pH 7; or R4 is a CH2ORb, where Rb=C1 to C6 alkyl or substituted alkyl groups, substituted or unsubstituted aryl, or a heteroaryl groups.
    Type: Grant
    Filed: June 12, 2018
    Date of Patent: July 7, 2020
    Assignees: Southern Methodist University, University of Central Florida Research Foundation, Inc.
    Inventors: John D. Buynak, Noora M. S. A. Al-Kharji, Weirui Chai, Thu Q. Nguyen, Maha Alqurafi, Kyle Rohde, Rashmi Gupta
  • Patent number: 10693085
    Abstract: A light-emitting element with a light-emitting substance comprising an organometallic complex. The organometallic complex having a structure represented by General Formula (G0). In the formula, X represents a substituted or unsubstituted six-membered heteroaromatic ring including two or more nitrogen atoms inclusive of a nitrogen atom that is a coordinating atom. Further, R1 and R2 each represent an alkyl group having 1 to 6 carbon atoms.
    Type: Grant
    Filed: December 8, 2017
    Date of Patent: June 23, 2020
    Assignee: Semiconductor Energy Laboratory Co., Ltd.
    Inventors: Hideko Inoue, Tomoya Yamaguchi, Hiromi Seo, Satoshi Seo, Kunihiko Suzuki, Miki Kanamoto
  • Patent number: 10689359
    Abstract: The invention relates to Crystal form I, Crystal form II and Crystal form III of N-(4-((3-chloro-4-fluorophenyl)amino)-7-((7-methyl-7-azaspiro[3.5]nonan-2-yl)methoxy)quinazolin-6-yl)acrylamide represented by the following Formula (I), and preparation methods thereof, wherein the Crystal form I has an X-ray powder diffraction pattern having characteristic peaks at the 2? positions of 6.7±0.2°, 7.9±0.2°, 8.6±0.2°, 12.0±0.2°, 13.9±0.2°, 15.9±0.2°, 17.3±0.2°, 18.3±0.2°, 18.7±0.2°, 21.0±0.2°, and 23.0±0.2°, as determined by using Cu-K? radiation; the Crystal form II has an X-ray powder diffraction pattern having characteristic peaks at the 2? positions of 6.9±0.2°, 8.5±0.2°, 14.8±0.2°, 15.6±0.2°, 16.7±0.2°, 17.1±0.2°, 17.9±0.2°, 18.7±0.2°, 19.1±0.2°, 21.5±0.2°, 23.5±0.2°, and 25.7±0.2°, as determined by using Cu-K? radiation; and the Crystal form III has an X-ray powder diffraction pattern having characteristic peaks at the 2? positions of 4.9±0.2°, 6.1±0.2°, 7.4±0.2°, 11.4±0.2°, 12.2±0.2°, 16.6±0.2°, and 18.4±0.
    Type: Grant
    Filed: December 23, 2016
    Date of Patent: June 23, 2020
    Assignee: Xuanzhu Pharma Co., Ltd.
    Inventors: Chutian Shu, Jinyuan Wang, Zhenhua Wang, Yuzhen Feng
  • Patent number: 10683315
    Abstract: The present invention relates to a prodrug and application thereof for the treatment of hepatitis C virus in patients.
    Type: Grant
    Filed: April 7, 2017
    Date of Patent: June 16, 2020
    Inventors: Alexandre Vasilievich Ivachtchenko, Oleg Dmitrievich Mitkin
  • Patent number: 10675283
    Abstract: Disclosed herein are compositions and methods for transitioning or converting a white adipocyte to a beige adipocyte. The compositions and methods may be used in the treatment of obesity. In some embodiments, the compositions include a compound selected from DC677 and DC761.
    Type: Grant
    Filed: March 26, 2018
    Date of Patent: June 9, 2020
    Assignees: University of South Florida, The United States Government as Represented by the Department Of Veterans Affairs
    Inventors: Denise Ratzlaff Cooper, Ryan Adam Kirchoffer, Robert Pleasants Sparks, Wayne Charles Guida
  • Patent number: 10676461
    Abstract: The present invention relates to N-((3S,4R)-1-((8-chloroquinoxalin-6-yl)carbonyl)-3-(4-fluorophenyl)piperidin-4-yl)-1-methyl-5-(trifluoromethyl)-1H-pyrazole-3-carboxamide, which is a compound that can be useful for the treatment or prevention of SPT-related diseases including congenital diseases associated with the storage of sphingolipids, such as cancer and Niemann-Pick disease, or a salt thereof.
    Type: Grant
    Filed: October 17, 2017
    Date of Patent: June 9, 2020
    Inventors: Katsunori Nagai, Takuto Kojima, Shinichi Imamura, Masao Hirakata
  • Patent number: 10676460
    Abstract: A compound of formula I wherein A, X, Y, Z, R1 and R24 are described herein. The compounds are useful as inhibitors of potassium channel function and in the treatment and prevention of arrhythmia, IKur-associated disorders, and other disorders mediated by ion channel function.
    Type: Grant
    Filed: January 9, 2019
    Date of Patent: June 9, 2020
    Assignee: Bristol-Myers Squibb Company
    Inventors: James A. Johnson, John Lloyd, Heather Finlay, James Neels, Naveen Kumar Dhondi, Prashantha Gunaga, Abhisek Banerjee, Ashokkumar Adisechan
  • Patent number: 10676472
    Abstract: The invention relates to crystalline salts of a compound having the structure of formula (I), methods for their preparation, and related pharmaceutical compositions comprising the crystalline salt. The invention further relates to methods of treating or preventing cancer or an immunological or neurological disease comprising administering a crystalline salt of the invention.
    Type: Grant
    Filed: June 7, 2019
    Date of Patent: June 9, 2020
    Assignee: Calithera Biosciences, Inc.
    Inventors: Timothy F. Stanton, James J. Springer, Jacqueline N. Williams
  • Patent number: 10669274
    Abstract: Disclosed are an azaphenalene-3-one derivative, its preparation method and its application, in the field of pharmaceutical synthesis. The derivative has the following Formula (I), wherein R is H, 2-fluoroethylamino, 2,2,2-trifluoroethylamino, diethylamino, pyrrolidinyl, imidazolyl, piperidinyl, morphinolinyl, 4-methylaminopiperidinyl, 4-dimethylaminopiperidinyl, (1-methylpiperidin-4-yl)methylamino, (1-phenylpiperidin-4-yl)methylamino, (1-benzylpiperidin-4-yl)methylamino, or 7-fluoro-3,4-dihydroisoquinoline-2(1H)-yl. The preparation method of the azaphenalene-3-one derivative is simple, the yield is high, post-treatment is easy, and purity is high. The derivative has high inhibitory activity against PARP enzyme. It establishes a foundation for researching better anti-tumor drugs using PARP inhibitors.
    Type: Grant
    Filed: May 24, 2018
    Date of Patent: June 2, 2020
    Inventors: Hao Zhang, Xiaodong Wang, Weiliang Xu, Weizheng Xu
  • Patent number: 10669279
    Abstract: The present invention is directed to compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein the substituents R1, R3, R6, R7, and b are as defined herein. The invention is also directed to pharmaceutical compositions comprising the compounds, methods of treatment using the compounds, and methods of preparing the compounds.
    Type: Grant
    Filed: June 27, 2019
    Date of Patent: June 2, 2020
    Assignee: Pfizer Inc.
    Inventors: Thomas Allen Chappie, Nandini Chaturbhai Patel, Matthew Merrill Hayward, Christopher John Helal, Simone Sciabola, Erik Alphie LaChapelle, Joseph Michael Young, Patrick Robert Verhoest
  • Patent number: 10662198
    Abstract: The present disclosure relates to polymorphic forms of the compound methyl (3R,6S)-6-amino-sulfonylamino-1-(thiazol-2-yl)-3-(2,3,4-trifluorophenyl)-3,5,6,7-tetrahydropyrrolo[1,2-c]pyrimidin-4-formate (compound 1). The present disclosure further relates to a pharmaceutical composition and pharmaceutical use and a preparation method of the polymorphic forms of compound 1.
    Type: Grant
    Filed: April 26, 2018
    Date of Patent: May 26, 2020
    Inventors: Jianwei Shen, Jin Zhang, Long Li, Yonghong Gao, Zhantao Zhang, Yong Zhang
  • Patent number: 10662197
    Abstract: Novel crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide free base and 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride, pharmaceutical compositions thereof and methods of their preparation and use are disclosed herein.
    Type: Grant
    Filed: September 28, 2018
    Date of Patent: May 26, 2020
    Assignee: Ariad Pharmaceuticals, Inc.
    Inventors: Christopher K. Murray, Leonard W. Rozamus, John J. Chaber, Pradeep K. Sharma
  • Patent number: 10662209
    Abstract: Large scale (bulk) compositions comprising high-purity stannsoporfin are disclosed, as well as methods of synthesizing such compositions.
    Type: Grant
    Filed: March 11, 2019
    Date of Patent: May 26, 2020
    Assignee: Mallinckrodt Hospital Products IP Limited
    Inventors: George S. Drummond, Robert Caroselli, Keith A. Cooke, Daniel Levin, David G. Roe, Christopher P. Boucher
  • Patent number: 10653701
    Abstract: Chemical entities that are kinase inhibitors, pharmaceutical compositions and methods of treatment of cancer are described.
    Type: Grant
    Filed: November 13, 2018
    Date of Patent: May 19, 2020
    Assignee: NEUPHARMA, INC.
    Inventors: Xiangping Qian, Yong-Liang Zhu
  • Patent number: 10653694
    Abstract: The invention relates to compounds which are inhibitors of the polymerization of tubulin, to the methods for the production thereof, and to the uses of same.
    Type: Grant
    Filed: April 9, 2015
    Date of Patent: May 19, 2020
    Inventors: Mouad Alami, Jean-Daniel Brion, Samir Messaoudi, Olivier Provot, Mohamed-Ali Soussi, Jerome Bignon, Joelle Dubois, Joanna Bakala-Wdzieczak
  • Patent number: 10647706
    Abstract: Novel chemokine CXCR1 and CXCR2 receptor antagonist compounds of general formula (I) are described. Also described, are pharmaceutical compositions including the compounds, and use of the compounds and the compositions for the treatment of chemokine-mediated pathologies, more specifically in the field of dermatology.
    Type: Grant
    Filed: April 2, 2019
    Date of Patent: May 12, 2020
    Inventors: Branislav Musicki, Yushma Bhurruth-Alcor